Obatoclax
Sign in to saveObatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals. Several Phase II clinical trials were completed that investigated use of obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.
Research
298 papers- Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy.Cells · 2023
- Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro.Emerging microbes & infections · 2022
- Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.Expert opinion on investigational drugs · 2012
- Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin Signaling.International journal of molecular sciences · 2020
- Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells.Journal of cellular biochemistry · 2014
via PubMed
Wikidata facts
- Mass
- 317.152812228
Show 4 more facts
- canonical SMILES
- COc1c/c(=C2/C=c3ccccc3=N2)[nH]/c1=C\c1[nH]c(C)cc1C
- chemical formula
- C₂₀H₁₉N₃O
- subject has role
- enzyme inhibitor
- isomeric SMILES
- COc1c/c(=C2/C=c3ccccc3=N2)[nH]/c1=C\c1[nH]c(C)cc1C
Sources (1)
via Wikidata · CC0
~1 min read
Encyclopedic overview
4 sectionsContents
- Mechanism of action
- Clinical trials
- See also
- References
Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals. Several Phase II clinical trials were completed that investigated use of obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.
==Mechanism of action==
Excerpted from Wikipedia’s “Obatoclax” article, available under the CC BY-SA 4.0 licence.